BRCA2 and hyperinsulinemic hypoglycemia, familial, 4: Targeting DNA damage response pathways has emerged as a promising anticancer strategy over the past decade; one case in which we have good insight is the synthetic lethality of PARP inhibitors and genetic HR deficiency caused by BRCA1 or BRCA2 mutations34–36.